Clinical Scorecard: GLP-1s Are Not the End of Bariatric Surgery; They’re the Beginning of Better Obesity Care

At a Glance

Key Highlights

• GLP-1 receptor agonists are not replacing bariatric surgery but enhancing obesity care.
• Oral GLP-1s provide an alternative for patients who prefer not to use injections.
• Less than 1% of eligible patients undergo bariatric surgery, while GLP-1s have reached a significant portion of the population.
• GLP-1s can optimize patients before surgery and help prevent weight gain recurrence post-surgery.
• Patient selection and shared decision-making are crucial for effective obesity treatment.

Guideline-Based Recommendations

Diagnosis

• Recognize obesity as a complex, chronic condition requiring comprehensive treatment.

Management

• Utilize a multimodal approach combining medications, lifestyle changes, and surgery as needed.

Monitoring & Follow-up

• Monitor weight loss progress and adjust treatment plans based on individual patient needs.

Risks

• Consider the limitations of GLP-1s, which may result in 10% to 20% total body weight loss on average.

Patient & Prescribing Data

Individuals with obesity, including those with high BMI and weight-related comorbidities.

Oral GLP-1s like semaglutide require specific dosing and adherence considerations.

Clinical Best Practices

• Engage in shared decision-making with patients regarding treatment options.
• Use GLP-1s to optimize patients preoperatively to reduce surgical risks.
• Educate patients about the physiological aspects of obesity to combat stigma.

Related Resources & Content

• Keck Medicine of USC